Categories: News

Blue Matter Launches Initiative Focused on Digital Health

NEW YORK, March 2, 2021 /PRNewswire/ — Blue Matter, a leading strategic consulting firm focused on the life sciences industry, has launched a new initiative to help life science companies develop and commercialize digital health solutions.

Digital health solutions encompass a variety of emerging products and services including digital therapeutics, digital biomarkers, digital medicine, clinical decision support tools, and adherence technologies.  Digital health aims to make healthcare more inclusive, accessible, and effective in treating nearly all types of conditions. The initiative acknowledges life science companies’ central role in engaging with a broader ecosystem of providers, payers, tech companies, and others to realize the potential of these innovations.

Digital therapeutics is a priority segment for the initiative and are defined as evidence-based therapeutic interventions driven by software with the intent to help prevent, manage, or treat a disease or disorder.  The range of interventions that can be classified as digital therapeutics is diverse.  They may be used as stand-alone or adjunctive treatments to medications, devices, or other therapies.

Blue Matter has appointed Jeff Liesch, Ph.D. to lead the initiative. Jeff is a Principal in Blue Matter’s New York office with an academic background in neurogenetics and behavior. He has cultivated expertise in digital health over the past few years.

“The field of digital therapeutics is growing rapidly, and there is an impressive range of possibilities.  It’s fascinating to repeatedly discover the potential for positive impact in just about every therapeutic area,” said Liesch. “Of course, they differ from traditional pharmacotherapies, which adds complexity during development and commercialization. Our goal is to develop a specialized set of strategic approaches and tools to help innovators develop digital therapeutics and successfully commercialize them.”

Liesch will propagate tools, approaches, and knowledge related to digital health throughout Blue Matter’s offices globally, ensuring that the firm is equipped to support clients in any location.

About Blue Matter
Blue Matter (www.bluematterconsulting.com) is a strategic consulting firm serving the life sciences industry. From its offices in North America and Europe, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio and organization levels, with a focus on commercial strategy for complex therapies in the development and launch stages. It has broad therapeutic experience with a concentration in oncology and rare diseases.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/blue-matter-launches-initiative-focused-on-digital-health-301238142.html

SOURCE Blue Matter Consulting

Staff

Recent Posts

Phio Pharmaceuticals Announces Reverse Stock Split

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"),…

3 hours ago

Alafair Biosciences Awarded Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap® Hydrogel Sheet

AUSTIN, Texas, July 2, 2024 /PRNewswire/ -- Alafair Biosciences, Inc., is revolutionizing soft tissue protection…

3 hours ago

PillBot™: Micro-robotics now inside the Human Body

HAYWARD, Calif., July 2, 2024 /PRNewswire/ -- Endiatx, a pioneering Silicon Valley medical technology company,…

3 hours ago

Digital Pathology Scanner Market Size to Grow USD 1,137 Million by 2030 at a CAGR of 10.31% | Valuates Reports

BANGALORE, India, July 2, 2024 /PRNewswire/ -- Digital Pathology Scanner Market is Segmented by Type (Fluorescence,…

3 hours ago

Medicus IT Ranked on Channel Futures 2024 MSP 501–Tech Industry’s Most Prestigious List of Managed Service Providers Worldwide

ALPHARETTA, Ga., July 2, 2024 /PRNewswire/ -- Medicus IT has been named as one of the…

3 hours ago